Loading stock data…
RPRX
$49.47-0.62 (-1.24%)
Market ClosedLast close May 1
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Royalty Pharma plc in the Healthcare sector is trading at $49.47. The stock is currently near its 52-week high of $50.47, remaining 22.8% above its 200-day moving average. Technical signals show neutral RSI of 60 and bearish MACD signal, explaining why RPRX maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 60) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$49.47
Potential Downside
24.3%
Whystock Fair Value$37.46
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$52.44+6.0%
Range$46.00 – $63.00
Fundamentals
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-sta...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$29.47B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
27.93
Beta
Defensive asset. Lower volatility than the S&P 500.
0.39
Div Yield
Strong income play. Yield provides a meaningful total return floor.
190.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.76%
Volume
Today's trading volume
2.32M
Recent News
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A Look At Royalty Pharma (RPRX) Valuation After Its Recent Share Price Momentum
Why Royalty Pharma (RPRX) Is Drawing Investor Attention Now Royalty Pharma (RPRX) is back on investor radars after a recent move in its share price, prompting a closer look at how its royalty driven model and current financial profile align with different portfolio goals. See our latest analysis for Royalty Pharma. At a share price of $49.38, Royalty Pharma has seen a 21.21% 90 day share price return and a 55.36% 1 year total shareholder return. This indicates that momentum has been building...
Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera
Zymeworks (NASDAQ:ZYME) used a presentation at the Bloom Burton conference to outline how the company is repositioning itself around its first approved product and a growing stream of royalty and milestone revenue, while continuing to invest in internal research and development across antibody-drug